Proshares Trust ZBIO
ZBIO
$28.47 +0.39 (+1.39%)
As of: Oct 22, 2026 · 12:27 PM EDT

Zenas BioPharma (ZBIO) Preferred Stock Liabilities (2023 - 2024)

Updated

Zenas BioPharma (ZBIO) recorded Preferred Stock Liabilities of $199.53 million in Q2 2024, up 3.2% from the prior quarter.

Analysis

Zenas BioPharma (ZBIO) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends

At the end of FY2023, Zenas BioPharma reported Preferred Stock Liabilities of $250.09 million.

  • Quarterly Preferred Stock Liabilities has ranged from $193.29 million in Q3 2023 to $250.09 million in Q4 2023 over the past five years.
  • Per Business Quant, the preceding three quarters came in at $193.29 million (Q1 2024), $250.09 million (Q4 2023) and $193.29 million (Q3 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,174.91 Bn 1,143.49 Bn 19.71 Bn -
2 Johnson & Johnson 644.40 Bn 562.93 Bn 17.26 Bn -
3 AbbVie 503.86 Bn 476.97 Bn 12.70 Bn -
4 Merck 379.74 Bn 334.12 Bn 12.21 Bn -
5 Novartis Ag 303.49 Bn 267.48 Bn 11.24 Bn -
6 Astrazeneca 269.36 Bn 243.04 Bn 12.86 Bn -
7 Amgen 243.43 Bn 198.83 Bn 7.24 Bn -
8 Gilead Sciences 194.04 Bn 168.24 Bn 6.22 Bn -
9 Pfizer 172.94 Bn 119.58 Bn 10.94 Bn -
10 Zenas BioPharma 1.80 Bn 1.12 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 199.53 Mn
Mar 31, 2024 193.29 Mn
Dec 31, 2023 250.09 Mn
Sep 30, 2023 193.29 Mn
API Access

Zenas BioPharma Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=ZBIO&period=max&api_key=YOUR_API_KEY